Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Journal of Steroid Biochemistry 28 (1987), S. 220 
    ISSN: 0022-4731
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Biology , Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0584
    Keywords: Key words PBPC autografting ; Apheresis results ; Hematopoietic recovery
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  One hundred and nine patients suffering from various malignancies underwent 285 apheresis procedures for PBPC collection. A median of two leukaphereses (range: 2–5) resulted in median numbers of 4.6×108 MNC/kg, 14.1×104 CFU-GM/kg, and 6.0×106 CD34+ cells/kg. Preleukapheresis peripheral blood CD34+ cells correlated significantly with collected CD34+ cells/kg (r=0.94;p〈0.0001) and with CFU-GM/kg (r=0.52;p〈0.0001). A value 〉4×104 CD34+ cells/ml was highly predictive for a collection yield 〉2.5×106 CD34+ cells/kg harvested by a single leukapheresis. Sixty patients were evaluated for hematologic reconstitution and engrafted in a median time of 10 days for WBC 〉1.0×109/l (range: 7–21 days), 10 days for ANC 〉0.5×109/l (7–20) and 11 days for PLT 〉20×109/l (7–62). Reinfused CD34+ cells/kg correlated significantly with hematologic engraftment (r=0.44–0.52 and p〈0.006–0.001) as well as CFU-GM/kg (r=0.36–0.44 and p〈0.007–0.001). A progenitor cell dose 〉2.5×106 CD34+ cells/kg or 〉8.0×104 CFUGM/kg led to a significantly faster recovery for WBC, ANC, and PLT when compared with patients receiving 〈2.5×106 CD34+ cells/kg or 〈8.0×104 CFU-GM/kg. We conclude that rapid hematopoietic engraftment after high-dose therapy and PBPC reinfusion correlates well with a progenitor cell dose 〉2.5×106 CD34+ cells/kg or 〉8.0×104 CFU-GM/kg, and that above a preleukapheresis threshold of 4×104 CD34+ cells/ml a PBPC autograft containing 〉2.5×106 CD34+ cells/kg can be collected by a single leukapheresis. We suggest that patients recovering from myelosuppression should be monitored for CD34+ cells in serial blood samples to determine the course of circulating hematopoietic progenitor cells. This issue will help to define the optimal time point to start apheresis and to predict a PBPC autograft harvested by a single leukapheresis, which will lead to rapid and stable hematopoietic reconstitution following transplantation.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-0584
    Keywords: PBPC autografting ; Apheresis results ; Hematopoietic recovery
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract One hundred and nine patients suffering from various malignancies underwent 285 apheresis procedures for PBPC collection. A median of two leukaphereses (range: 2–5) resulted in median numbers of 4.6×108 MNC/kg, 14.1×104 CFU-GM/kg, and 6.0×106 CD34+ cells/kg. Preleukapheresis peripheral blood CD34+ cells correlated significantly with collected CD34+ cells/kg (r=0.94;p〈0.0001) and with CFU-GM/kg (r=0.52;p〈0.0001). A value 〉4×104 CD34+ cells/ml was highly predictive for a collection yield 〉2.5×106 CD34+ cells/kg harvested by a single leukapheresis. Sixty patients were evaluated for hematologic reconstitution and engrafted in a median time of 10 days for WBC 〉1.0×109/l (range: 7–21 days), 10 days for ANC 〉0.5×109/l (7–20) and 11 days for PLT 〉20×109/l (7–62). Reinfused CD34+ cells/kg correlated significantly with hematologic engraftment (r=0.44–0.52 andp〈0.006–0.001) as well as CFU-GM/ kg (r=0.36–0.44 andp〈0.007–0.001). A progenitor cell dose 〉2.5×106 CD34+ cells/kg or 〉8.0×104 CFU-GM/kg led to a significantly faster recovery for WBC, ANC, and PLT when compared with patients receiving 〈2.5×106 CD34+ cells/kg or 〈 8.0×104 CFU-GM/kg. We conclude that rapid hematopoietic engraftment after high-dose therapy and PBPC reinfusion correlates well with a progenitor cell dose 〉2.5×106 CD34+ cells/kg or 〉8.0×104 CFU-GM/kg, and that above a preleukapheresis threshold of 4×104 CD34+ cells/ml a PBPC autograft containing 〉2.5×106 CD34+ cells/kg can be collected by a single leukapheresis. We suggest that patients recovering from myelosuppression should be monitored for CD34+ cells in serial blood samples to determine the course of circulating hematopoietic progenitor cells. This issue will help to define the optimal time point to start apheresis and to predict a PBPC autograft harvested by a single leukapheresis, which will lead to rapid and stable hematopoietic reconstitution following transplantation.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-0584
    Keywords: Keywords PBSC mobilization failure ; Poor mobilizers ; Bone marrow harvest
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  We assessed autologous bone marrow (BM) harvest and hematologic recovery after high-dose chemotherapy (HDCT) in patients who failed to achieve peripheral blood stem cell (PBSC) mobilization. One hundred and ninety-three patients with germ cell tumor, malignant lymphoma, sarcoma or medulloblastoma were scheduled for HDCT. In 123 patients, PBSC were mobilized by disease-specific chemotherapy plus granulocyte colony-stimulating factor (G-CSF). In 110/123 patients (89%) with circulating CD34+ cell counts ≥10/μl, sufficient hematopoietic autografts were collected (group A). In 13/123 patients (11%) with peripheral CD34+ cell counts 〈10/μl, PBSC harvesting was not performed (group B). These latter patients were classified as "poor mobilizers" and underwent second-line BM harvest at a median of 46 (range 10–99) days after mobilization failure. Seventy patients with first-line BM harvest (group C) acted as historical controls. Ten patients from group B proceeded to HDCT and nine were evaluable for hematopoietic reconstitution. Recovery to neutrophils 〉0.5×109/l was comparable with group C patients: 16 (range 9–34) days vs 13 (range 8–98) days. However, platelet (PLT) reconstitution 〉20×109/l was significantly slower, with a median of 35 (range 13–50) days as compared with 19 (range 9–148) days (P=0.0106) for control patients. Supportive care requirements, febrile days and length of hospital stay were not significantly different between the two groups of patients. We conclude that patients who fail to mobilize PBSC should be evaluated for second-line BM harvest. This approach may preserve the therapeutic option of HDCT for these patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...